Jenny L Craigen

Title: Jenny L Craigen: Innovator in Multiple Myeloma Prognosis

Introduction

Jenny L Craigen is a notable inventor based in Stevenage, GB. She has made significant contributions to the field of medical research, particularly in the prognosis and treatment of multiple myeloma. Her innovative work has led to the development of methods that can greatly enhance patient care.

Latest Patents

Jenny holds a patent for a prognostic method that determines the prognosis of multiple myeloma in patients by measuring the expression of BCMA in a sample. This patent also includes methods for treating multiple myeloma by administering an effective amount of an antigen binding protein that binds to BCMA. Additionally, she has developed kits for measuring BCMA expression in samples, which can be crucial for effective treatment planning.

Career Highlights

Jenny is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where she continues to work on innovative solutions in the healthcare sector. Her dedication to improving patient outcomes through research and development is commendable.

Collaborations

Jenny has collaborated with esteemed colleagues such as Danton Bounds and William E Fieles, contributing to a dynamic team focused on advancing medical technologies.

Conclusion

Jenny L Craigen's work in the field of multiple myeloma prognosis and treatment exemplifies the impact of innovation in healthcare. Her contributions are paving the way for improved patient outcomes and advancing medical research.